CO2024009565A2 - Composición farmacéutica que comprende budesonida para tratamiento de la nefropatía iga - Google Patents
Composición farmacéutica que comprende budesonida para tratamiento de la nefropatía igaInfo
- Publication number
- CO2024009565A2 CO2024009565A2 CONC2024/0009565A CO2024009565A CO2024009565A2 CO 2024009565 A2 CO2024009565 A2 CO 2024009565A2 CO 2024009565 A CO2024009565 A CO 2024009565A CO 2024009565 A2 CO2024009565 A2 CO 2024009565A2
- Authority
- CO
- Colombia
- Prior art keywords
- budesonide
- dissolution medium
- iga nephropathy
- treatment
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263302226P | 2022-01-24 | 2022-01-24 | |
| US202263302216P | 2022-01-24 | 2022-01-24 | |
| GBGB2217146.6A GB202217146D0 (en) | 2022-11-16 | 2022-11-16 | New pharmaceutical compositions |
| GBGB2217150.8A GB202217150D0 (en) | 2022-11-16 | 2022-11-16 | New pharmaceutical compositions |
| PCT/EP2023/051680 WO2023139285A1 (en) | 2022-01-24 | 2023-01-24 | Pharmaceutical composition comprising budesonide for treating iga nephropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024009565A2 true CO2024009565A2 (es) | 2024-09-19 |
Family
ID=85076189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0009565A CO2024009565A2 (es) | 2022-01-24 | 2024-07-19 | Composición farmacéutica que comprende budesonida para tratamiento de la nefropatía iga |
Country Status (14)
| Country | Link |
|---|---|
| US (10) | US11896719B2 (enExample) |
| EP (1) | EP4469060A1 (enExample) |
| JP (1) | JP2025508321A (enExample) |
| KR (2) | KR20250008979A (enExample) |
| CN (6) | CN120754111A (enExample) |
| AU (1) | AU2023210461A1 (enExample) |
| CA (1) | CA3249575A1 (enExample) |
| CL (1) | CL2024002201A1 (enExample) |
| CO (1) | CO2024009565A2 (enExample) |
| GE (1) | GEAP202416588A (enExample) |
| IL (1) | IL314067A (enExample) |
| MX (1) | MX2024009024A (enExample) |
| TW (2) | TW202547520A (enExample) |
| WO (1) | WO2023139285A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11896719B2 (en) | 2022-01-24 | 2024-02-13 | Calliditas Therapeutics Ab | Pharmaceutical compositions |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4123403A (en) | 1977-06-27 | 1978-10-31 | The Dow Chemical Company | Continuous process for preparing aqueous polymer microsuspensions |
| US4502888A (en) | 1982-12-13 | 1985-03-05 | The Dow Chemical Company | Aqueous dispersions of plasticized polymer particles |
| US5643602A (en) * | 1989-11-22 | 1997-07-01 | Astra Aktiebolag | Oral composition for the treatment of inflammatory bowel disease |
| SE8903914D0 (sv) | 1989-11-22 | 1989-11-22 | Draco Ab | Oral composition for the treatment of inflammatory bowel diseases |
| DE69425453T2 (de) | 1993-04-23 | 2001-04-12 | Novartis Ag, Basel | Wirkstoffabgabevorrichtung mit gesteuerter Freigabe |
| DE4332394A1 (de) | 1993-09-23 | 1995-03-30 | Falk Pharma Gmbh | Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung |
| US5482718A (en) * | 1994-03-23 | 1996-01-09 | Hoffmann-La Roche Inc. | Colon-targeted delivery system |
| GB9412394D0 (en) | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
| DE4446891A1 (de) | 1994-12-27 | 1996-07-04 | Falk Pharma Gmbh | Stabile wäßrige Budesonid-Lösung |
| SG80553A1 (en) | 1995-07-20 | 2001-05-22 | Tanabe Seiyaku Co | Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract |
| GB9516268D0 (en) | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
| GB9722426D0 (en) | 1997-10-23 | 1997-12-24 | Univ London Pharmacy | Controlled release formulations |
| US6239120B1 (en) | 1998-03-17 | 2001-05-29 | Pharmalink Ab | Method and means for treating glomerulonephritis |
| SE514128C2 (sv) * | 1998-03-17 | 2001-01-08 | Pharmalink Ab | Användning av en glukokortikoid för framställning av ett läkemedel för behandling av glomerulonefrit |
| CA2377301C (en) | 1999-06-14 | 2009-05-12 | Cosmo S.P.A. | Controlled release and taste masking oral pharmaceutical compositions |
| US8895064B2 (en) * | 1999-06-14 | 2014-11-25 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
| DE10004939C1 (de) | 2000-02-05 | 2001-08-23 | Lothar Moerl | Steuerbare Gasanströmeinrichtung für Strahlschichtapparate |
| DE10013029A1 (de) | 2000-03-17 | 2001-09-20 | Roehm Gmbh | Mehrschichtige Arzneiform für die Colonfreigabe |
| ITRM20010614A1 (it) | 2001-10-16 | 2003-04-16 | Italchimici S P A | Preparazione farmaceutica di una soluzione idro/propilenica di budesonide e suo procedimento di preparazione. |
| DE10162781A1 (de) | 2001-12-20 | 2003-07-03 | Glatt Ingtech Gmbh | Strahlschichtapparat zur chargenweisen oder kontinuierlichen Prozessführung und Verfahren zum Betreiben eines Strahlschichtapparates |
| DE10214002A1 (de) | 2002-03-27 | 2003-10-09 | Roehm Gmbh | Pharmazeutische Formulierung für den Wirkstoff Budesonid |
| DE10250543A1 (de) | 2002-10-29 | 2004-05-19 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform |
| WO2004052607A1 (en) | 2002-12-10 | 2004-06-24 | Cps Orocel Llc | Method of preparing biologically active formulations |
| DE10322062A1 (de) | 2003-05-15 | 2004-12-02 | Glatt Ingenieurtechnik Gmbh | Verfahren und Vorrichtung zum Aufbringen von Flüssigkeiten in eine Feststoffströmung eines Strahlschichtapparates |
| DE10325989A1 (de) | 2003-06-07 | 2005-01-05 | Glatt Gmbh | Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung |
| AR041873A1 (es) | 2003-10-30 | 2005-06-01 | Pablo Cassara Srl Lab | Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante |
| DE102004043863A1 (de) | 2004-09-10 | 2006-03-16 | Nitec Pharma Ag | Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum |
| DE102005037630A1 (de) | 2005-08-09 | 2007-02-15 | Glatt Gmbh | Verfahren zur Herstellung von Teilchen aus pharmazeutischen Substanzen, Teilchen aus pharmazeutischen Substanzen sowie deren Verwendung |
| DE102005060393A1 (de) | 2005-12-16 | 2007-06-21 | Add Advanced Drug Delivery Technologies Ltd. | Orales Präparat mit kontrollierter Freisetzung |
| CN101108171A (zh) | 2006-07-17 | 2008-01-23 | 复旦大学 | 一种布地奈德肠溶缓释微丸及其制备方法 |
| EP2002835A1 (en) | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| US20090004281A1 (en) | 2007-06-26 | 2009-01-01 | Biovail Laboratories International S.R.L. | Multiparticulate osmotic delivery system |
| JP2011506607A (ja) | 2007-12-17 | 2011-03-03 | ザリカス インコーポレイティッド | 免疫炎症性障害の処置のための治療法 |
| GB0808537D0 (en) * | 2008-05-12 | 2008-06-18 | Archimedes Dev Ltd | Compositions |
| EP2166010A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166008A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166009A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| US8945616B2 (en) * | 2009-02-17 | 2015-02-03 | Mylan Pharmaceuticals Inc. | Controlled release budesonide minitablets |
| NZ599933A (en) | 2009-11-03 | 2014-08-29 | Lipidor Ab | Lipid layer forming composition for administration onto a surface of a living organism |
| JP2014510064A (ja) | 2011-02-25 | 2014-04-24 | ザ ジョンズ ホプキンス ユニバーシティ | Ｎｒｆ２活性剤としてのカルコン誘導体 |
| AU2012251135A1 (en) | 2011-05-02 | 2013-11-07 | Lipidor Ab | Treatment of psoriasis |
| US10034943B2 (en) | 2011-05-02 | 2018-07-31 | Lipidor Ab | Sprayable topical carrier and composition comprising phosphatidylcholine |
| EP2591782A1 (en) | 2011-11-11 | 2013-05-15 | Johann Wolfgang Goethe-Universität | Nadph oxidase 4 inhibitors and use thereof |
| WO2013078261A1 (en) | 2011-11-22 | 2013-05-30 | The University Of Maryland, Baltimore | Treatment of muscular conditions and muscular dystrophies |
| EP2857399A1 (en) | 2013-10-03 | 2015-04-08 | GenKyoTex SA | Compounds useful for the treatment of PDE5 inhibitor-poorly responsive erectile dysfunction |
| IN2013MU03373A (enExample) | 2013-10-25 | 2015-07-17 | Cadila Healthcare Ltd | |
| WO2015071812A1 (en) | 2013-11-18 | 2015-05-21 | Wockhardt Limited | Solid oral modified-release composition comprising budesonide or salt thereof |
| GB201419257D0 (en) | 2014-10-29 | 2014-12-10 | Jagotec Ag | Pharmaceutical compositions |
| EP3034500A1 (en) | 2014-12-17 | 2016-06-22 | Genkyotex Sa | Amido thiazole derivatives as NADPH oxidase inhibitors |
| US20190125678A1 (en) | 2015-01-30 | 2019-05-02 | Mylan, Inc. | Sustained-Release Oral Dosage Forms for Low Aqueous Solubility Compounds |
| EP3098220A1 (en) | 2015-05-28 | 2016-11-30 | GenKyoTex SA | Process for the preparation of a nadph oxidase inhibitor and its polymorphs and uses thereof |
| US9707182B2 (en) | 2015-09-11 | 2017-07-18 | Sun Pharmaceutical Industries Ltd. | Oral pharmaceutical dosage forms of budesonide |
| AR106330A1 (es) | 2015-10-13 | 2018-01-03 | Flexion Therapeutics Inc | Formulaciones de corticoesteroide para mantener las concentraciones de corticoesteroide en líquido sinovial |
| CN105663091A (zh) | 2016-01-28 | 2016-06-15 | 上海信谊百路达药业有限公司 | 一种布地奈德肠溶缓释胶囊及其制备方法 |
| US11590084B2 (en) | 2016-05-02 | 2023-02-28 | Roman Bielski | Microcapsules for controlled delivery of an active pharmaceutical ingredient |
| US10286036B2 (en) | 2017-05-12 | 2019-05-14 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| EP3479843A1 (en) | 2017-11-01 | 2019-05-08 | GenKyoTex Suisse SA | Use of nox inhibitors for treatment of cancer |
| CA3091443A1 (en) | 2018-02-22 | 2019-08-29 | Avior, Inc. | Transmucosal film composition and methods of making and using the same |
| EP3553081A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Atrial natriuretic peptide engrafted antibodies |
| WO2020011938A1 (en) | 2018-07-11 | 2020-01-16 | Medizinische Universität Wien | Glucocorticoids for the topical treatment of autoimmune gastritis |
| EP3628669A1 (en) | 2018-09-28 | 2020-04-01 | GenKyoTex Suisse SA | Novel compounds as nadph oxidase inhibitors |
| CN110507627B (zh) | 2019-09-29 | 2021-11-02 | 重庆医药高等专科学校 | 一种布地奈德的口服控释药物组合物 |
| WO2021127003A1 (en) | 2019-12-16 | 2021-06-24 | Children's Medical Center Corporation | Treating heart disease in muscular dystrophy patients |
| CN112999229B (zh) | 2019-12-19 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 一种包含布地奈德的口服药物组合物 |
| US20240197639A1 (en) | 2021-04-20 | 2024-06-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Capsule for specific drug delivery and preparation method therefor |
| TW202302116A (zh) | 2021-04-20 | 2023-01-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 口服腸溶皮質類固醇的藥物組合物 |
| CN115737597A (zh) | 2021-09-02 | 2023-03-07 | 江苏豪森药业集团有限公司 | 一种口服的肠溶速释药物组合物、制备方法及其应用 |
| US11896719B2 (en) * | 2022-01-24 | 2024-02-13 | Calliditas Therapeutics Ab | Pharmaceutical compositions |
| US20240033225A1 (en) * | 2022-01-24 | 2024-02-01 | Calliditas Therapeutics Ab | Pharmaceutical compositions |
-
2023
- 2023-01-23 US US18/100,396 patent/US11896719B2/en active Active
- 2023-01-24 KR KR1020247043208A patent/KR20250008979A/ko active Pending
- 2023-01-24 CN CN202510929056.3A patent/CN120754111A/zh active Pending
- 2023-01-24 WO PCT/EP2023/051680 patent/WO2023139285A1/en not_active Ceased
- 2023-01-24 IL IL314067A patent/IL314067A/en unknown
- 2023-01-24 CA CA3249575A patent/CA3249575A1/en active Pending
- 2023-01-24 CN CN202510935869.3A patent/CN120754112A/zh active Pending
- 2023-01-24 KR KR1020247027521A patent/KR102919268B1/ko active Active
- 2023-01-24 EP EP23701946.8A patent/EP4469060A1/en active Pending
- 2023-01-24 CN CN202510116905.3A patent/CN120053463A/zh active Pending
- 2023-01-24 CN CN202510943983.0A patent/CN120754113A/zh active Pending
- 2023-01-24 CN CN202610075373.8A patent/CN121796407A/zh active Pending
- 2023-01-24 AU AU2023210461A patent/AU2023210461A1/en active Pending
- 2023-01-24 CN CN202610075378.0A patent/CN121774982A/zh active Pending
- 2023-01-24 JP JP2024543526A patent/JP2025508321A/ja active Pending
- 2023-01-24 GE GEAP202416588A patent/GEAP202416588A/en unknown
- 2023-01-30 TW TW114134366A patent/TW202547520A/zh unknown
- 2023-01-30 TW TW112103187A patent/TWI896928B/zh active
- 2023-12-21 US US18/392,602 patent/US12171882B2/en active Active
- 2023-12-21 US US18/392,666 patent/US12171883B2/en active Active
-
2024
- 2024-07-19 MX MX2024009024A patent/MX2024009024A/es unknown
- 2024-07-19 CO CONC2024/0009565A patent/CO2024009565A2/es unknown
- 2024-07-22 CL CL2024002201A patent/CL2024002201A1/es unknown
- 2024-11-01 US US18/934,978 patent/US12311057B2/en active Active
-
2025
- 2025-04-30 US US19/195,082 patent/US20250255824A1/en active Pending
- 2025-04-30 US US19/194,972 patent/US20250268835A1/en active Pending
- 2025-06-18 US US19/242,380 patent/US20250312283A1/en active Pending
- 2025-06-18 US US19/242,077 patent/US20250312282A1/en active Pending
- 2025-08-19 US US19/304,103 patent/US20250381147A1/en active Pending
- 2025-08-19 US US19/303,799 patent/US20250381146A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Acuña‐Castroviejo et al. | Clinical trial to test the efficacy of melatonin in COVID‐19 | |
| CO2024009565A2 (es) | Composición farmacéutica que comprende budesonida para tratamiento de la nefropatía iga | |
| BR0211317A (pt) | Sistema para a liberação controlada de uma droga por meio de retenção gástrica | |
| ES2109899T1 (es) | Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos. | |
| AU2011263730B2 (en) | Treatment of Type 2 diabetes | |
| MEP28208A (en) | Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure | |
| AR040709A1 (es) | Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion | |
| Booth et al. | Subarachnoid meperidine (Pethidine) causes significant nausea and vomiting during labor | |
| AR063138A1 (es) | Comprimidos pediatricos de capecitabina | |
| Gholizadeh et al. | Intralesional corticosteroid injection as an effective treatment method for oral lesions: a meta-analysis | |
| Zang et al. | Ginkgo biloba extract (EGb-761) confers neuroprotection against ischemic stroke by augmenting autophagic/lysosomal signaling pathway | |
| CO5570661A2 (es) | Combinaciones que comprenden inhibidores de cox-2 y aspirina | |
| AR054238A1 (es) | Composicion farmaceutica que contiene una biguanida y un derivado de tiazolidindiona | |
| CO5190664A1 (es) | Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2 | |
| DOP2025000253A (es) | Compuestos de derivados de ácido indazol propiónico sustituidos y usos de estos | |
| CO2026000726A2 (es) | Una forma farmacéutica sólida de dosificación bucodispersable de safinamida | |
| ES2917982T3 (es) | Método para tratar trastornos hepáticos | |
| Yahiaoui et al. | Intravenous methylprednisolone induced acute pancreatitis | |
| Rich et al. | Nonsteroidal anti-inflammatory drug gastropathy at the new millennium: mechanisms and prevention | |
| CA3199000A1 (en) | Composition containing 1,8-cineole for therapeutic use | |
| AR053928A1 (es) | Metodos reactivos para el tratamiento de trastornos inflamatorios | |
| Unal et al. | Priapism–A rare side effect of alpha blockers: Report of 2 cases and literature review | |
| Warren et al. | Regional Enteritis: Report of Forty-Three Cases | |
| Kurt et al. | Effect of ovariectomy and female sex hormones administration upon gastric ulceration induced by cold and immobility restraint stress | |
| Miyake et al. | Pathological consideration of tracheo-innominate artery fistula with a case report |